CareDx price target raised to $17 from $14 at Piper Jaffray. Piper Jaffray analyst William Quirk raised his price target for CareDx to $17 after the company hosted sessions at the American Transplant Congress on Tuesday. User experiences hinted at the longer-term potential of AlloSure, Quirk tells investors in a research note. The analyst continue to believes that CareDx has one of the most attractive opportunities in diagnostics and he’s now incrementally more confident in the early launch. He reiterates an Overweight rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.